Date: 2016-09-23
Type of information: Development agreement
Compound:
Company: Allergan (Ireland) Rugen Therapeutics (China)
Therapeutic area: Mental diseases - CNS diseases
Type agreement: development
Action mechanism:
Disease: autism spectrum disorders, obsessive compulsive disorders
Details: * On November 25, 2015, Allergan and Rugen Therapeutics, a start-up biotechnology company focused on the development of novel treatments for unmet CNS disorders and funded by the F-Prime Biomedical Research Initiative (FBRI), announced that they have entered into an exclusive collaboration to support the discovery and development of novel therapies for Autism Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD). As part of the collaboration, Allergan and Rugen will jointly focus on the development of novel small molecule drug candidates. The research collaboration initially includes early stage compounds, which are first-in-class orally active molecules being developed for multiple CNS disorders. Rugen has demonstrated efficacy for its compounds in animal models of ASD and OCD. Compounds Allergan is working to develop with Rugen are currently in preclinical development.
Financial terms: Under the terms of the agreement, Rugen received an upfront initiation fee at the outset of the collaboration, and is entitled to development stage initiation and success-based milestone payments for advancing compounds in development. Allergan will have the exclusive option to acquire all rights, including the worldwide intellectual property rights and other assets, related to the compounds following clinical proof of concept studies.
Latest news:
